This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Devos, G. et al. ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer. Eur. Urol. https://doi.org/10.1016/j.eururo.2022.09.009 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fenner, A. ARNEO: neoadjuvant degarelix + apalutamide before surgery for high-risk prostate cancer. Nat Rev Urol 19, 634 (2022). https://doi.org/10.1038/s41585-022-00664-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-022-00664-4